These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 29285755)

  • 1. Pharmaceutical Benefits Scheme listing of adalimumab for hidradenitis suppurativa: Is hidradenitis suppurativa a life-changing drug or does lifestyle change the drug?
    Vekic DA; Frew JW
    Australas J Dermatol; 2018 Aug; 59(3):e243-e244. PubMed ID: 29285755
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful treatment of recalcitrant gluteal hidradenitis suppurativa with brodalumab after anti-TNF failure.
    Arenbergerova M; Arenberger P; Marques E; Gkalpakiotis S
    Int J Dermatol; 2020 Jun; 59(6):733-735. PubMed ID: 32012238
    [No Abstract]   [Full Text] [Related]  

  • 3. MABp1 Targeting IL-1α for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study.
    Kanni T; Argyropoulou M; Spyridopoulos T; Pistiki A; Stecher M; Dinarello CA; Simard J; Giamarellos-Bourboulis EJ
    J Invest Dermatol; 2018 Apr; 138(4):795-801. PubMed ID: 29129600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guselkumab in the treatment of hidradenitis suppurativa: A retrospective chart review.
    Casseres RG; Kahn JS; Her MJ; Rosmarin D
    J Am Acad Dermatol; 2019 Jul; 81(1):265-267. PubMed ID: 30562567
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical response rate and flares of hidradenitis suppurativa in the treatment with adalimumab.
    Caposiena Caro RD; Cannizzaro MV; Tartaglia C; Bianchi L
    Clin Exp Dermatol; 2020 Jun; 45(4):438-444. PubMed ID: 31630436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa.
    Morita A; Takahashi H; Ozawa K; Imafuku S; Nakama T; Takahashi K; Matsuyama T; Okubo Y; Kitamura S; Matsuda N; Zhao Y; Yokoyama M; Hayashi N; Terui T
    J Dermatol; 2019 Sep; 46(9):745-751. PubMed ID: 31282051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data.
    Frew JW; Jiang CS; Singh N; Grand D; Navrazhina K; Vaughan R; Krueger JG
    J Am Acad Dermatol; 2020 May; 82(5):1150-1157. PubMed ID: 31881294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic Treatment for Hidradenitis Suppurativa.
    Flood KS; Porter ML; Kimball AB
    Am J Clin Dermatol; 2019 Oct; 20(5):625-638. PubMed ID: 31140067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience with adalimumab biosimilar imraldi in hidradenitis suppurativa.
    Ricceri F; Rosi E; Di Cesare A; Pescitelli L; Fastame MT; Prignano F
    Dermatol Ther; 2020 Nov; 33(6):e14387. PubMed ID: 33030281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
    Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD
    J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adalimumab: A Review in Hidradenitis Suppurativa.
    Kim ES; Garnock-Jones KP; Keam SJ
    Am J Clin Dermatol; 2016 Oct; 17(5):545-552. PubMed ID: 27665300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab.
    Harde V; Mrowietz U
    J Dtsch Dermatol Ges; 2009 Feb; 7(2):139-41. PubMed ID: 19371236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Achieving Hidradenitis Suppurativa Response Score is Associated with Significant Improvement in Clinical and Patient-reported Outcomes: Post Hoc Analysis of Pooled Data From PIONEER I and II.
    Kimball AB; Tzellos T; Calimlim BM; Teixeira HD; Geng Z; Okun MM
    Acta Derm Venereol; 2018 Nov; 98(10):932-937. PubMed ID: 30085324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hidradenitis suppurativa in association with keratitis-ichthyosis-deafness syndrome treated with adalimumab.
    Song YM; Kim YS; Lee JH; Park YM; Lee JY
    J Dermatol; 2018 Sep; 45(9):e262-e263. PubMed ID: 29570225
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical experience of the use of adalimumab in the management of hidradenitis suppurativa. Comparison of response rates with Crohn disease.
    Moyano B; Clemente A; Marín-Jiménez I; Martorell A
    Actas Dermosifiliogr; 2016 Sep; 107 Suppl 2():43-50. PubMed ID: 28081769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is it worthy to treat hidradenitis suppurativa with adalimumab in patients with melanoma and other debilitating systemic diseases? A series of clinical dilemmas.
    Zhao CY; Fernández-Peñas P
    Australas J Dermatol; 2018 Nov; 59(4):e297-e298. PubMed ID: 29672833
    [No Abstract]   [Full Text] [Related]  

  • 17. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.
    Kimball AB; Sobell JM; Zouboulis CC; Gu Y; Williams DA; Sundaram M; Teixeira HD; Jemec GB
    J Eur Acad Dermatol Venereol; 2016 Jun; 30(6):989-94. PubMed ID: 26201313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose adalimumab biosimilar (ZRC-3197) in the treatment of hidradenitis suppurativa.
    Patil S
    Indian J Dermatol Venereol Leprol; 2018; 84(6):745-747. PubMed ID: 30289113
    [No Abstract]   [Full Text] [Related]  

  • 19. A Genetic Variant in the BCL2 Gene Associates with Adalimumab Response in Hidradenitis Suppurativa Clinical Trials and Regulates Expression of BCL2.
    Liu M; Degner J; Georgantas RW; Nader A; Mostafa NM; Teixeira HD; Williams DA; Kirsner RS; Nichols AJ; Davis JW; Waring JF
    J Invest Dermatol; 2020 Mar; 140(3):574-582.e2. PubMed ID: 31465739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and Ultrasonographic Profile of Adalimumab-treated Hidradenitis Suppurativa Patients: A Real-life Monocentric Experience.
    Chiricozzi A; Giovanardi G; Garcovich S; Malvaso D; Caldarola G; Fossati B; Guerriero C; De Simone C; Peris K
    Acta Derm Venereol; 2020 Jun; 100(13):adv00172. PubMed ID: 32421198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.